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The mesoderm- and epithelial-mesenchymal transi-
tion-associated transcription factor FOXC1 is specif-
ically overexpressed in basal-like breast cancer
(BLBC), but its biochemical function is not under-
stood. Here, we demonstrate that FOXC1 controls
cancer stem cell (CSC) properties enriched in BLBC
cells via activation of Smoothened (SMO)-indepen-
dent Hedgehog (Hh) signaling. This non-canonical
activation of Hh is specifically mediated by Gli2.
Furthermore, we show that the N-terminal domain
of FOXC1 (aa 1–68) binds directly to an internal region
(aa 898–1168) of Gli2, enhancing the DNA-binding
and transcription-activating capacity of Gli2. FOXC1
expression correlates with that of Gli2 and its targets
in human breast cancers. Moreover, FOXC1 overex-
pression reduces sensitivity to anti-Hedgehog (Hh)
inhibitors in BLBC cells and xenograft tumors.
Together, these findings reveal FOXC1-mediated
non-canonical Hh signaling that determines the
BLBC stem-like phenotype and anti-Hh sensitivity,
supporting inhibition of FOXC1pathways aspotential
approaches for improving BLBC treatment.
INTRODUCTION
Breast cancer is a heterogeneous disease that consists of
multiple molecular subtypes characterized by distinct patho-
physiological features. By using high-throughput technologies,1046 Cell Reports 13, 1046–1058, November 3, 2015 ª2015 The Autbreast cancer has been classified into at least four biologically
distinct subtypes: luminal A, luminal B, human epidermal growth
factor receptor 2-overexpressing (HER2+), and basal like
(Koboldt et al., 2012). Basal-like breast cancer (BLBC) accounts
for 15%–20% of all invasive breast cancers and is associated
with high histologic grade, younger patient age, and poor prog-
nosis (Rakha et al., 2008). Estrogen receptor-positive (ER+)
tumors of the luminal subtype can be treated with endocrine
therapy, whereas HER2+ tumors may benefit from antibody or
small-molecule inhibitor drugs. In contrast, chemotherapy re-
mains the only systemic treatment modality for BLBC.
Recent studies have shown that forkhead box C1 (FOXC1), a
transcription factor involved in the development of mesoderm,
brain, and eye during embryogenesis (Kume et al., 1998;
Maclean et al., 2005), may serve as a key diagnostic biomarker
specific for BLBC (Jensen et al., 2015; Ray et al., 2010). Elevated
expression of FOXC1 also predicts poor overall survival in other
cancers such as lung cancer (Wei et al., 2013) and hepatocellular
carcinoma (Xia et al., 2013). A recent study has shown that
NF-kB signaling mediates the function of FOXC1 in BLBC cell
proliferation and invasion (Wang et al., 2012). Consistent with
this result, matrix metalloprotease-7 (MMP7), which is regulated
by NF-kB, mediates the invasion-promoting function of FOXC1
in BLBC (Sizemore and Keri, 2012).
Accumulating evidence indicates that cancer stem cells
(CSCs) contribute to tumor growth, metastasis, and relapse,
and that FOXC1 contributes to the CSC phenotype. Gene
expression profiles suggest a less differentiated progenitor cell
phenotype or a stem cell origin for BLBC (Ben-Porath et al.,
2008; Zvelebil et al., 2013). In addition, BLBC is enriched with
cells of the CD44+/CD24– phenotype (Honeth et al., 2008), which
possess tumor-initiating stem-like properties (Al-Hajj et al.,hors
Figure 1. FOXC1 Increases CSC Properties
in BLBC Cells In Vivo and In Vitro
(A) Tumor incidence rates of different dilutions of
control and FOXC1-overexpressing MDA-MB-231
cells injected into the fourth mammary fat pads of
BALB/c nude mice.
(B) 33 106 control and FOXC1-knockdown BT549
cells were injected into the fourth mammary fat
pads of NOD/SCID mice (n = 8).
(C) Representative flow cytometry analysis of
ALDH+ cells in control and FOXC1-overexpressing
MDA-MB-231 cells. The bar graph indicates
mean ± SD. ***p < 0.001.
(D) Representative flow cytometry analysis of
ALDH+ cells in control and FOXC1-knockdown
BT549 cells. The bar graph indicates mean ± SD.
***p < 0.001.
(E) Mammosphere growth in control and FOXC1-
overexpressing MDA-MB-231 cells. The bar graph
indicates mean ± SD. **p < 0.01.
(F) Mammosphere growth in control and FOXC1-
knockdown BT549 cells. The bar graph indicates
mean ± SD. ***p < 0.001.
See also Figure S1.2003). A recent study showed that the FOXC1 protein is exclu-
sively expressed in basal cells but that FOXC1mRNA is enriched
in luminal progenitor cells (Sizemore et al., 2013). In line with this
finding, FOXC1 induces a progenitor-like phenotype in differenti-
atedmammary epithelial cells (Bloushtain-Qimron et al., 2008). In
tumor cells, FOXC1 can induce epithelial-mesenchymal transi-
tion (EMT) (Xia et al., 2013; Yu et al., 2013), a cellular feature asso-
ciated with CSCs (Mani et al., 2008). Most recently, FOXC1 is
reported to be a key regulator for development andmaintenance
of the mesenchymal niches for hematopoietic stem and progen-
itor cells (Omatsu et al., 2014). To date, it is unclear how FOXC1
interacts with or orchestrates signaling pathways involved in
BLBC cell function and stem-like properties. To address this
question, we explored the effects of FOXC1 on CSC properties
in vivo and in vitro and the potential underlying mechanisms.
Wehave identified FOXC1 as aSmoothened (SMO)-independent
activator of Hedgehog (Hh) signaling via direct interaction with
the Gli2 transcription factor. We also characterized the involve-
ment of FOXC1 in the BLBC cell response to anti-SMO inhibitors.
RESULTS
FOXC1 Increases CSC Properties in BLBC Cells In Vivo
and In Vitro
Because FOXC1 emerges as a critical biomarker for BLBC and
induces the CSC-associated EMT phenotype, we set out toCell Reports 13, 1046–1058, Ndirectly test the effect of FOXC1 on
CSC properties in vivo by performing
limiting dilution injection experiments.
FOXC1 was stably overexpressed in
MDA-MB-231 cells (Figure S1A). Serial
dilutions of control or FOXC1-overex-
pressing cells were injected orthotopi-
cally into the fourth mammary glands ofBALB/c nude mice, and tumor growth was examined. As pre-
sented in Figure 1A, there were no differences in the tumor inci-
dence when 100,000 or 10,000 cells were injected. However,
when as few as 1,000 or 100 cells were inoculated, seven or
three out of eight injections of FOXC1-overexpressing cells
developed tumors respectively, as opposed to two or zero out
of eight injections of control cells. Notably, when FOXC1-knock-
down BT549 cells were injected into the mouse mammary
glands, tumorigenesis was completely inhibited (Figure 1B).
CSC can also be identified by specific biomarkers in vitro in
many types of cancer.Widely used biomarkers for characterizing
breast CSC include elevated aldehyde dehydrogenase (ALDH)
activity (Ginestier et al., 2007), CD133+ (Wright et al., 2008),
and CD44+/CD24– (Al-Hajj et al., 2003). Breast CSC can also
be propagated in vitro as mammospheres, which are spherical
clusters of cells in non-adherent culture conditions (Ponti et al.,
2005). Using the ALDEFLUOR assay followed by flow cytometry,
we observed that ALDH activity was enhanced greater than
3-fold in FOXC1-overexpressing cells (Figure 1C). Conversely,
when we knocked down FOXC1 using shRNAs in BT549 cells
(Figure S1A), which express high levels of endogenous FOXC1,
ALDH activity was dramatically reduced (Figure 1D). To further
validate the effect of FOXC1 on ALDH activity in BLBC cells,
we also overexpressed FOXC1 in SUM159 and MDA-MB-468
cells (Figure S1A). As expected, ALDH activity was significantly
increased by FOXC1 in these two cell lines (Figure S1B). Inovember 3, 2015 ª2015 The Authors 1047
agreement, knockdown of endogenous FOXC1 in SUM149 cells
markedly inhibited ALDH activity (Figures S1A and S1B). The
mammosphere formation ability of MDA-MB-231 cells was
substantially increased by FOXC1 overexpression (Figure 1E).
Similar results were found in FOXC1-overexpressing SUM159
cells (Figure S1C). Of note, mammosphere growth was abol-
ished by FOXC1 knockdown in BT549 cells (Figure 1F). Likewise,
mammosphere formation in FOXC1-knockdown SUM149 cells
was also repressed (Figure S1C).
We also examined the effect of FOXC1 expression on the
CD133+ population. As shown in Figure S1D, overexpression of
FOXC1 increased the CD133+ population in both MDA-MB-231
and SUM159 cells, whereas knockdown of FOXC1 reduced the
CD133+ population in both BT549 and SUM149 cells. We further
explored the regulation of the CD44+CD24– breast CSC marker.
Although no changes were observed in FOXC1-overexpressing
MDA-MB-468 or FOXC1-knockdown BT549 cells, the CD44+
CD24– population was indeed increased by FOXC1 overexpres-
sion in SUM159 cells (Figure S1E). Conversely, knockdown of
FOXC1 reduced the population in SUM149 cells (Figure S1E).
Of note, parental BT549 and MDA-MB-231 cells showed high
CD44+CD24– populations (Figure S1E), as described previously
(Ricardo et al., 2011), suggesting that these subpopulations
may not represent CSCs in the two cell lines. Taken together,
these results demonstrate that FOXC1 positively regulates CSC
properties of BLBC cells in vivo and in vitro.
It has been reported that transformation from a luminal primary
to a basal-like recurrence is more likely than the opposite phe-
nomena (Castaneda et al., 2012). Recent studies showed that
FOXC1 is associated with mesenchymal circulating tumor cells
from both ER+ and ER– breast cancer and may induce EMT in
ER+ breast cancer cells (Yu et al., 2013). Thus, we explored the
effect of FOXC1 on CSC properties in two ER+ cell lines, MCF7
andT47D,which harbor undetectable FOXC1 levels (Figure S1A).
Likewise, FOXC1 overexpression in these cells increased ALDH
activity (Figure S1B), mammosphere formation (Figure S1C), and
the CD44+CD24– population (Figure S1E), but not the CD133+
cell percentage (Figure S1D). Together, these results further sub-
stantiate a role of FOXC1 in CSCs.
FOXC1 Activates SMO-Independent Hedgehog
Signaling in BLBC Cells
Studies have shown that CSCs share many features with normal
stem cells, including self-renewal and differentiation as well as
the signaling mechanisms governing the stemness property
(Magee et al., 2012). Three well-known classical signaling path-
ways involved in the normal stem cell function are the Wnt, Hh,
and Notch pathways, which are also implicated in breast cancer
development and CSC maintenance (Lobo et al., 2007). Hence,
we first examined whether FOXC1 can activate these pathways.
Todo this,weperformedpathway-specific binding site luciferase
reporter assays, which measure the extent of activation of these
three pathways. As shown in Figure 2A, FOXC1 potently induced
Hh-responsive luciferase (8 3 30Gli-binding site [BS]-luciferase)
(Sasaki et al., 1997) activity in different BLBC cell lines. Similar
results were observed in MCF7 and T47D cells (Figure S2A).
In contrast, FOXC1 did not significantly induce Wnt or Notch
pathway-specific luciferase activity (Figures S2B and S2C).1048 Cell Reports 13, 1046–1058, November 3, 2015 ª2015 The AutTo confirm the activation of Hh signaling by FOXC1, we exam-
ined the expression of genes known to be induced by the activa-
tion of the Hh signaling. Using real-time PCR assays, we found
that the mRNA levels of human hedgehog interacting protein
(Hhip) and Patched1 (Ptch1) were significantly upregulated by
FOXC1 in different BLBC cell lines (Figure 2B). In support of
these observations, higher levels of endogenous FOXC1 were
found to be associated with more robust Gli-BS luciferase activ-
ity in multiple breast cancer cell lines, which were transfected
with the same amount of the 8 3 30Gli-BS-luciferase construct
(Figure 2C). Taken together, these results demonstrate that
FOXC1 activates the Hh signaling pathway in BLBC cells.
In canonical mammalian Hh signaling, SMO is the central
signal transducer (Robbins et al., 2012). Surprisingly, SMO
mRNA and protein were not detected in MDA-MB-231 or
HCC1500 cells, even though FOXC1 activates Hh signaling in
these two cell lines (Figure 2D). On the other hand, although
SUM159 and SUM1315 cells express readily detectable SMO
(Figure 2D), FOXC1-induced Gli-BS-luciferase activity was not
affected by small interfering RNA (siRNA)-mediated SMO knock-
down (Figures 2E and 2F). Similar results were found in luminal
MCF7 and T47D cells (Figures S2D and S2E). To substantiate
these results, we examined the effects of the two SMO inhibitors
GDC-0449 (Vismodegib) and LDE225 (Sonidegib) on FOXC1-
induced Hh signaling. As expected, neither of them reduced
FOXC1-induced Gli-BS-luciferase activity in SMO-positive
(SUM159 and T47D) or SMO-negative (MDA-MB-231 and
MCF7) breast cancer cells (Figures 2G, 2H, S2F, and S2G). On
the contrary, when the cells were treated with another Hh
pathway inhibitor, GANT61, which directly targets the DNA-bind-
ing ability of Gli proteins (Lauth et al., 2007), FOXC1-induced
Gli-BS-luciferase activity was considerably attenuated (Figures
2I and S2H). To further verify that FOXC1 activates SMO-
independent Hh signaling, we treated SHH-Light2, a clonal
NIH 3T3 cell line stably transfected with 8 3 30Gli-BS-luciferase
construct (Taipale et al., 2000), with Hh signaling agonist amino-
terminal domain of SHH (SHH-N). FOXC1 significantly induced
luciferase activity when SMO was inhibited by GDC-0449
(Figure 2J) or LDE225 (Figure 2K). These results demonstrate
that FOXC1-induced activation of Hh signaling in BLBC cells is
SMO independent.
Gli2 Mediates FOXC1-Induced CSC Properties
The ultimate effectors in the mammalian Hh signaling are the
three transcription factors Gli1, Gli2, and Gli3. They bind directly
to gene promoters through zinc-finger motifs and regulate the
expression of target genes involved in diverse cell functions
(Hui and Angers, 2011). To determine their individual role in the
FOXC1-induced activation of Hh signaling, we knocked down
the expression of Gli1, Gli2, or Gli3 in MDA-MB-231 cells using
siRNAs (Figure S3A). Interestingly, only Gli2, but not Gli1 or
Gli3 knockdown, decreased FOXC1-induced Gli-BS-luciferase
activity (Figure 3A; Figures S3B and S3C) as well as Hhip and
Ptch1 mRNA expression levels (Figure 3B). To corroborate that
Gli2 is responsible for the activation of Hh signaling by FOXC1,
we treated cells with arsenic trioxide (ATO), which inhibits Hh
signaling by preventing Gli2 ciliary accumulation and promoting
its degradation (Kim et al., 2010). As illustrated in Figures S3Dhors
Figure 2. FOXC1 Activates SMO-Independent Hh Signaling in BLBC Cells
(A) Cells were transfected with vector or FOXC1 plasmids and wild-type or mutant 8 3 30Gli-BS-luciferase plasmids. Luciferase assay was performed. The bar
graph indicates mean ± SD. ***p < 0.001.
(legend continued on next page)
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and S3E, ATO inhibited FOXC1-induced Gli-BS-luciferase
activity and Hhip and Ptch1 mRNA expression. These results
implicate Gli2 as a mediator of FOXC1-induced activation of
Hh signaling.
We proceeded to determine whether the induction of CSC
properties by FOXC1 in BLBC cells is mediated by Gli2. For
this purpose, we repressed Gli2 expression using shRNAs in
FOXC1-overexpressing MDA-MB-231 cells (Figure S3F). The
ALDEFLUOR assay showed that elevated ALDH activity and
mammosphere formation capacity in FOXC1-overexpressing
cells were markedly suppressed by Gli2 knockdown (Figures
3C and 3E). Likewise, when Gli2 was knocked down in BT549
cells (Figure S3G), ALDH activity and mammosphere growth
were markedly reduced (Figures 3D and 3F), which resembles
the effects of FOXC1 knockdown on ALDH activity andmammo-
sphere growth in BT549 cells (Figures 1D and 1F). We next
re-expressed mouse Gli2, whose expression was not affected
by human Gli2 shRNA, in the Gli2-knockdown FOXC1-overex-
pressing MDA-MB-231 cells. As shown in Figures S3H and
S3I, the Gli2-knockdown-induced decrease of ALDH activity
and mammosphere growth was partially rescued by mouse
Gli2 overexpression. Next, we injected different numbers of
control or Gli2-knockdown FOXC1-overexpressing MDA-
MB-231 cells into the mammary fat pads of BALB/c nude
mice. The results showed that Gli2 knockdown attenuated
FOXC1-induced tumorigenicity (Figure 3G). Taken together,
these results suggest that Gli2 is a critical mediator of the effects
of FOXC1 on tumorigenesis andCSC properties of breast cancer
cells.
FOXC1 Interacts with Gli2 in BLBC Cells
Next, we investigated how FOXC1 engages Gli2 in its regulation
of breast CSC properties. Because activation of SMO-indepen-
dent Hh signaling can be induced by upregulation of Gli expres-
sion (Lauth and Toftga˚rd, 2007), we first tested whether FOXC1
regulates Gli2 expression in breast cancer cells. Real-time
PCR and western blotting analysis showed that FOXC1 did not
affect Gli2 mRNA or protein levels in MDA-MB-231 cells (Figures
S4A and S4B). Furthermore, western blotting of cytoplasmic and
nuclear lysates and immunofluorescence staining indicated that
FOXC1 did not alter the intracellular distribution of the Gli2
protein, which wasmainly localized in the nucleus in both control
and FOXC1-overexpressing MDA-MB-231 cells (Figures S4C
and S4D).
Given that both FOXC1 and Gli2 are transcription factors, we
assessed whether these two proteins can interact with each(B) Real-time PCR analysis of gene expression levels in control or FOXC1-overex
***p < 0.001.
(C) Endogenous FOXC1, Gli1, Gli2, and Gli3 protein levels in breast cancer cell li
wild-type or mutant 8 3 30Gli-BS-luciferase plasmids. Data (mean ± SD) represe
(D) SMO mRNA and protein levels were measured by RT-PCR and western blott
(E and F) Cells were first transfected with wild-type 83 30Gli-BS-luciferase and vec
siRNAs for an additional 48 hr. SMO knockdown was confirmed by western blottin
(G–I) Cells were transfected with wild-type 8 3 30Gli-BS-luciferase and vector o
and GANT61 (I) at different concentrations for 24 hr. Luciferase assay was perfo
(J and K) SHH-Light2 cells were transfected with vector or FOXC1 plasmids. Ce
assay was performed. The bar graph indicates mean ± SD. ***p < 0.001.
See also Figure S2.
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and Gli2 constructs into HEK293T cells and performed immuno-
precipitation (IP) assays. As shown in Figure 4A, overexpressed
FOXC1 and Gli2 were co-immunoprecipitated from HEK293T
cells with anti-FOXC1 or anti-Gli2 antibodies. Similar results
were found in FOXC1-overexpressing MDA-MB-231 cells with
relatively high levels of endogenous Gli2 (Figure 4B). In addition,
coimmunoprecipitation (coIP) of the two proteins was also
detected in BT549 cells, which possess high levels of both
endogenous FOXC1 and Gli2 (Figure 4C). Consistent with our
results, coIP of FOXC1 and Gli2 has been recently reported in
a study of endochondral ossification (Yoshida et al., 2015).
To test whether the binding between these two proteins is
direct, which no other factors are involved, we expressed His-
tagged-FOXC1 and glutathione S-transferase (GST) tagged-
Gli2 in E. coli BL21 (DE3) and performed GST and His pull-down
assays. As presented in Figure 4D (left), the GST-Gli2 bait inter-
acted directly with His-FOXC1. Reciprocally, the His-FOXC1 bait
captured GST-Gli2 (Figure 4D, right). To confirm the direct inter-
action of these two proteins, we performed the fluorescence
resonance energy transfer (FRET) assay, which is commonly
used to assess the proximity of two proteins. As demonstrated
in Figure 4E, a significant increase in donor fluorescence was
found after bleaching acceptor fluorescence, suggesting that
FRET occurred between FOXC1 and Gli2. We measured FRET
efficiency for each individual cell. The measured FRET efficiency
was 50% ± 3% (n = 15) (Table S1), indicating consistently high
proximity of the proteins in the cells. In agreement with the above
results, colocalization was observed in the nucleus of HEK293T
cells transfected with FOXC1 and Gli2 (Figure S4E). These data
suggest that FOXC1 and Gli2 bind directly to each other in
BLBC cells.
Next, we aimed to identify the FOXC1 domain that participates
in this interaction. With this in view, we constructed His-tagged
expression vectors for truncated FOXC1 mutants comprising
the N-terminal, DNA-binding, transcription-inhibitory, and C-ter-
minal domains (Berry et al., 2002) (Figure 4F, left). These con-
structs and GST-Gli2 were expressed in E. coli BL21 (DE3),
and proteins were purified, followed by coIP assays. Western
blotting results showed that only the FOXC1 mutants containing
the N-terminal domain (aa 1–68), but not other mutants, bind
directly to the Gli2 protein (Figure 4F, right). We also constructed
mammalian expression vectors for Myc-tagged truncated
FOXC1 mutants and ectopically expressed them in MDA-
MB-231 cells (Figure S4F). Likewise, the FOXC1 fragment of aa
1–178, which contains the N-terminal domain (aa 1–68), waspressing BLBC cells. The bar graph indicates mean ± SD. *p < 0.05, **p < 0.01,
nes were measured by western blotting. The same cells were transfected with
nt relative luciferase activity compared to that in MDA-MB-231 cells.
ing, respectively.
tor or FOXC1 plasmids for 24 hr and thenwere transfectedwith control or SMO
g (E). Luciferase assay was performed (F). The bar graph indicates mean ± SD.
r FOXC1 plasmids. Cells were then treated with GDC-0449 (G), LDE225 (H),
rmed. The bar graph indicates mean ± SD. **p < 0.01, ***p < 0.001.
lls were then treated with SHH-N and GDC-0449 (J) or LDE225 (K). Luciferase
hors
Figure 3. FOXC1-Induced Activation of Hh
Signaling and Increase of CSC Properties in
BLBC Cells Is Mediated by Gli2
(A and B) MDA-MB-231 cells were first transfected
with wild-type 8 3 30Gli-BS-luciferase and vector
or FOXC1 plasmids for 24 hr and then transfected
with control or Gli1, Gli2, or Gli3 siRNAs for an
additional 48 hr. Luciferase assay (A) and real-time
PCR (B) were performed. The bar graph indicates
mean ± SD (n = 3). **p < 0.01.
(C) Representative flow cytometry analysis of
ALDH+ cells in control or Gli2-knockdown FOXC1-
overexpressing MDA-MB-231 cells. The bar graph
indicates mean ± SD. ***p < 0.001.
(D) Representative flow cytometry analysis of
ALDH+ cells in control and Gli2-knockdown
BT549 cells. The bar graph indicates mean ± SD.
**p < 0.01, ***p < 0.001.
(E) Mammosphere growth in control or Gli2-
knockdown FOXC1-overexpressing MDA-MB-231
cells. The bar graph indicates mean ± SD.
***p < 0.001.
(F) Mammosphere growth in control and Gli2-
knockdown BT549 cells. The bar graph indicates
mean ± SD. **p < 0.01; ***p < 0.001.
(G) Tumor incidence rates of different dilutions of
control or Gli2-knockdown FOXC1-overexpressing
MDA-MB-231 cells injected into the fourth mam-
mary fat pads of BALB/c nude mice.
See also Figure S3.found to interact with endogenous Gli2 (Figure S4G). Of note, the
expression of the N-terminal domain (aa 1–68) was not detect-
able inMDA-MB-231 cells. Alternatively, this fragment was fused
with GFP and successfully overexpressed in MDA-MB-231 cells
(Figure S4H). As expected, the FOXC1 protein fragment was co-
immunoprecipitated with Gli2 (Figure S4H). In line with these
results, luciferase assays revealed that the FOXC1 mutants
comprising aa 1–68 induced Gli-BS-luciferase activity similar
to the full-length FOXC1 (Figure S4I). Taken together, these
data demonstrate that FOXC1 directly interacts with Gli2 via its
N-terminal domain (aa 1–68).Cell Reports 13, 1046–1058, NWe then proceeded to identify the Gli2
domain involved in the binding to
FOXC1. The Gli2 protein consists of an
N-terminal domain, a zinc finger DNA-
binding domain, and a C-terminal domain
(Figure 4G, left) (Li et al., 2014). We con-
structed mammalian expression vectors
for Myc-tagged truncated Gli2 mutants.
These constructs were transfected into
HEK293T cells together with FOXC1,
followed by coIP assays. Western blotting
results indicated that only the Gli2 con-
structs containing aa 898–1168, but not
other constructs, bound to FOXC1 (Fig-
ure 4G, right). Using site-directed muta-
genesis, we also generated a mutant
mouse Gli2 that lacks aa 891–1154, corre-
sponding to human Gli2 aa 898–1168. Asexpected, this Gli2 deletion mutant could not rescue the Gli2-
knockdown-elicited phenotypes of ALDH activity and mammo-
sphere formation (Figures S3H and S3I). These results suggest
that the aa 898–1168 region in Gli2 mediates its binding to
FOXC1.
Gli1 andGli2 are the twomajor mediators for Hh-induced gene
transcription. We have shown that Gli1 is not involved in the
effect of FOXC1 on transcriptional activity of Gli proteins (see
Figure 3A), suggesting that FOXC1 may not interact with Gli1.
To corroborate this, we transfected HEK293T cell with both
FOXC1 and Gli1 and then performed coIP assay. As shown inovember 3, 2015 ª2015 The Authors 1051
Figure 4. FOXC1 Interacts Directly with Gli2
in BLBC Cells
(A–C) CoIP analysis of the interaction between
FOXC1 and Gli2. Assays were performed in
HEK293T cells transfected with both FOXC1 and
Gli2 plasmids (A), FOXC1-overexpressing MDA-
MB-231 cells (B), and BT549 cells (C).
(D) GST (left) and His (right) pull-down assays for
the interaction between His-FOXC1 andGST-Gli2.
His-FOXC1 and GST-Gli2 were expressed in
E. coli BL21 (DE3) and purified.
(E) FRET analysis for the direct interaction be-
tween FOXC1 and Gli2. HEK293T cells were
transfected with FOXC1 and Gli2, followed by
immunofluorescence. Scale bar, 25 mm.
(F) Illustration of full-length and truncated FOXC1
(left). GST-Gli2 and His-tag full-length or truncated
FOXC1 were expressed in E. coli BL21 (DE3).
Purified proteins were mixed and subjected to
coIP analysis (right).
(G) Illustration of full-length and truncated Gli2
(left). FOXC1 and Myc-tagged full-length or trun-
cated Gli2 were transfected into HEK293T cells.
Proteins were harvested and subjected to coIP
analysis (right).
See also Figures S4 and S5.Figure S4J, no interaction was detected between the two pro-
teins. We also compared the sequence of Gli2 (aa 898–1168)
with the corresponding region of Gli1 and found no significant
homology between the two regions (Figure S4K).
Structural Model of FOXC1-Gli2 Interaction
We then used the above interaction information to construct an
atomistic model of the interaction interface in the proposed
FOXC1-Gli2 complex (see Supplemental Experimental Proce-
dures for details). The top four interaction poses by energy
of FOXC11–684 with Gli2898–1168 are shown in Figure S5A (referred
to as 4_10, 4_64, 4_68, 4_77). Table S2 lists all the favorable
interactions seen in these four interaction models. Models 4_64,1052 Cell Reports 13, 1046–1058, November 3, 2015 ª2015 The Authors4_68, and 4_77 are similar to each other
and different from model 4_10. Model
4_77 was chosen for mutagenesis experi-
ments because, of the four best models
chosen by energy, it had themost interac-
tions (Table S2). The residues chosen for
mutation are shown in Figure S5B by
gray boxes. To validate the computational
structuralmodelof the interaction,wecon-
structed the mutant shown in Figure S5B
based on model 4_77 and performed
coIP assays. As predicted, no interaction
was observed between FOXC1 and
mutant Gli2 (aa 898–1168) when FOXC1
and Myc tag antibodies were used to
immunoprecipitate the FOXC1 protein
and the Gli2 fragment, respectively (Fig-
ure S5E), indicating the critical role of the
mutated residues in the FOXC1-Gli2 inter-action. These residues provide structural hints and complex 4_77
provides an informative structural model for the direct interaction
observed in this study between FOXC1 and Gli2.
Furthermore, structural modeling showed that the binding of
FOXC1 to Gli2 can allosterically change (open) the DNA binding
domain of Gli2 (Figure S5F), providing a structural hypothesis for
how FOXC1 binding to Gli2 can potentially promote the DNA
binding capacity of Gli2.
FOXC1 Promotes the DNA-Binding Ability of Gli2 in
BLBC Cells
Next, we examined whether FOXC1 enhances the DNA-binding
ability of Gli2. It was noted that there is a consensus Gli2-binding
Figure 5. FOXC1 Promotes Gli2 DNA-Binding Capacity
(A) ChIP assay for the binding of Gli2 to the FAM38B gene promoter in control,
FOXC1-overexpressing, and Gli2-knockdown FOXC1-overexpressing MDA-
MB-231 cells. DNA protein complexes immunoprecipitated by Gli2 antibody
and immunoglobulin G (IgG) were analyzed by RT-PCR and real-time PCR.
The bar graph indicates mean ± SD (n = 3). **p < 0.01; ***p < 0.001.
(B) EMSA assay for the binding of Gli2 to the FAM38B gene promoter in control
and FOXC1-overexpressing MDA-MB-231 cells. The biotin-labeled Gli-bind-
ing DNA or mutant Gli-binding DNA was used. Epstein-Barr virus nuclear
antigen (EBNA) binding sequence was used as a positive control.
(C) Biotinylated oligonucleotide precipitation assay for the binding of Gli2 to
the FAM38B gene promoter in control and FOXC1-overexpressing MDA-
MB-231 cells (left) and in MDA-MB-231 cells transfected with FOXC1 trun-
cates (right). The biotin-labeled Gli-binding DNA was used.site GACCACCCA in the promoter of FAM38B gene, which
was markedly upregulated by FOXC1 overexpression in MDA-
MB-231 cells as revealed by microarray assays (GEO:
GSE73234). Using the chromatin immunoprecipitation (ChIP)
assay, we found that FOXC1 enhanced the binding of Gli2 to
the FAM38B promoter in MDA-MB-231 cells, and this enhance-
ment was eliminated by Gli2 knockdown (Figure 5A). Next, we
performed the electrophoretic mobility shift assay (EMSA) assay.
Synthesized biotin-labeled 21-bp oligos containing the wild-typeCell Reor mutant Gli2-binding site in the FAM38B promoter were used
as the probes. As shown in Figure 5B, FOXC1 overexpression
led to an upward mobility shift of oligos in gels, reflecting
increased binding of Gli2 to the biotin-labeled oligos. FOXC1-
induced augmentation of Gli2 DNA-binding capacity was further
substantiated by the biotinylated oligonucleotide precipitation
assay. Using the biotin-labeled oligonucleotides comprising
the Gli2 binding site from the FAM38B promoter, Gli2 was found
to be pulled down with FOXC1 in FOXC1-overexpressing MDA-
MB-231 cells (Figure 5C, left). Similar result was found when
MDA-MB-231 cells were transfected with the FOXC1 fragment
(aa 1–178), which comprises the Gli2-binding (aa 1–68) and
DNA-binding (forkhead) domains (Figure 5C, right). However,
overexpression of the FOXC1 fragment of aa 367–553, which is
not involved in the binding of FOXC1 to Gli2, did not induce the
binding of Gli2 to the biotin oligos (Figure 5C, right). These
data indicate that FOXC1 promotes the DNA-binding capacity
of Gli2 in breast cancer cells.
Expression of FOXC1 Correlates with the Activation of
the Hedgehog Signaling in Clinical Samples
To assess the clinical significance of FOXC1-induced activation
of the Hh signaling, we evaluated the expression levels of FOXC1
and Gli2 using immunohistochemistry (IHC) in human breast
cancers. Because FOXC1 is specifically expressed in BLBC or
triple-negative breast cancer (TNBC), and the majority of TNBCs
display a basal-like phenotype (Han et al., 2013), we performed
IHC staining on TNBC tissue microarrays. FOXC1 and Gli2
were readily detectable in 54.2% and 81.3% of cases, respec-
tively, and a strong correlation between the expressions of the
two proteins was found (Figures 6A and 6B). We also evaluated
the expression of Ptch1 and Hhip proteins. Significant correla-
tions were also observed between FOXC1 and Ptch1 as well
as between FOXC1 and Hhip (Figures 6A, 6C, and 6D). Analysis
of The Cancer Genome Atlas (TCGA) database and Curtis data
set (Curtis et al., 2012) showed that the mRNA levels of FOXC1
strongly correlate with those of Gli2 and Ptch1 in breast cancer
samples (Figures 6E and S6A). Even though the correlation
between FOXC1 and Hhip was not statistically significant in
TCGA samples, a significant association between them was
observed in a Singapore cohort data set (Figure S6C). We also
performed multiple regression analysis, which incorporated
13 Hh pathway-associated genes (see Statistics in Supple-
mental Experimental Procedures) in the three cohort data sets.
A strong correlation between FOXC1 levels and Hh pathway
activation was found in all three data sets (Figures 6F, S6B,
and S6D). We further tested whether the Hh gene signature
correlates with breast cancer prognosis. Using K-means clus-
tering, two groups of patients with either positively (n = 378) or
negatively (n = 1,608) enriched Hh pathway-associated genes
were found in the Curtis data set. As illustrated in Figure 6G,
the former group was associated with elevated FOXC1 expres-
sion levels (47.03 ± 2.98 versus 8.54 ± 0.36, p < 0.0001) and
decreased disease-specific survival that was statistically signif-
icant compared to the latter group (hazard ratio [HR] = 1.973,
95% confidence interval [CI] = 1.802–2.961, p < 0.0001). Taken
together, these data suggest a positive correlation between
FOXC1 and the activation of Hh signaling in clinical samples.ports 13, 1046–1058, November 3, 2015 ª2015 The Authors 1053
Figure 6. FOXC1 Correlates with Hh
Pathway Activation in Clinical Samples
(A) Representative IHC results in TNBC tissue
microarray samples. Scale bar, 50 mm.
(B–D) Correlation analysis of FOXC1 and Gli2 (B),
FOXC1 and Ptch1 (C), and FOXC1 and Hhip (D)
based on the IHC staining results. Linear regres-
sion analysis was performed.
(E) Correlation analysis between FOXC1 and Gli2,
Ptch1, Hhip in TCGA samples (n = 526). Linear
regression analysis was performed.
(F) Correlation analysis between FOXC1 and 13 Hh
pathway-associated genes (see Statistics section
in Experimental Procedures) in TCGA samples
(n = 526). Multiple regression analysis was per-
formed.
(G) Kaplan Meier curves of percentage of disease-
specific survival of two groups of patients from the
Curtis data set that were either positively (n = 378)
or negatively (n = 1,608) enriched for the 13 Hh
pathway-associated genes. Log-rank test was
performed to calculate p value.
See also Figure S6.FOXC1 Reduces Sensitivity to Anti-SMO Drugs in BLBC
Cells
Since the Hh signaling is critically involved in tumorigenesis
and CSC function, many efforts have gone into developing
anti-Hh inhibitors for anti-cancer therapy. GDC-0449, a SMO-
targeting inhibitor, has been approved by FDA for the treatment
of basal cell carcinoma. Hh inhibition is also in clinical trials
for triple-negative breast cancers (https://clinicaltrials.gov/,
NCT01757327). Because FOXC1 activates Hh signaling via a
SMO-independent manner, we reasoned that elevated expres-
sion of FOXC1 may render cancer cells refractory to SMO-tar-
geting inhibitors. To address this question, we analyzed the
effects of GDC-0449 on cell viability in control and FOXC1-
overexpressing BLBC cells. Cell viability assays showed that
elevated expression of FOXC1 reduced the sensitivity to
GDC-0449 in different SMO-positive BLBC cell lines (Figures
7A–7D). In agreement with this result, the mRNA expression
levels of Ptch1 and Hhip were inhibited by GDC-0449 in these1054 Cell Reports 13, 1046–1058, November 3, 2015 ª2015 The Authorscells, and this GDC-0449 effect was
attenuated by FOXC1 overexpression
(Figure S7A). We also generated GDC-
0449-resistant BLBC sublines by long-
term culture of parental cells in the
presence of increasing concentrations
of GDC-0449. As illustrated in Figure 7E,
the derived GDC-0449-resistant cells
possessed higher expression levels
of FOXC1. Interestingly, when FOXC1
was repressed by siRNAs in these cells,
the acquired GDC-0449 resistance
was attenuated (Figures S7B–S7E). We
then tested the effect of FOXC1 on
GDC-0449-induced tumor growth inhibi-
tion in vivo by orthotopic injection of con-
trol and FOXC1-overexpressing MDA-MB-468 cells into the mouse mammary glands. As shown in
Figure 7F, GDC-0449 impeded the growth of control group tu-
mors, whereas overexpression of FOXC1 abolished this inhibi-
tory effect. Taken together, these results indicate that the
expression of FOXC1 renders cancer cells refractory to SMO-
targeting drugs, which has clinical implications for ongoing
investigations of anti-Hh inhibitors in breast cancer therapy.
DISCUSSION
BLBC has been shown to possess intrinsic CSC properties
(Ben-Porath et al., 2008; Honeth et al., 2008), which may
explain in part the aggressive clinical behavior of this breast
cancer subtype. The findings reported in this study provide a
mechanism underlying the aggressiveness and poor prognosis
of BLBC and establish FOXC1 as a promising therapeutic
target for BLBC treatment. Interestingly, FOXC2, another mem-
ber of the FOX family, has also been shown to regulate CSCs in
Figure 7. FOXC1 Induces Resistance to Anti-
Hh Drug
(A–D) Relative cell viability and EC50 of GDC-0449 in
control or FOXC1-overexpressing MDA-MB-468
cells treated with the recombinant N-terminal frag-
ment of the Sonic hedgehog protein (SHH-N) (A),
MDA-MB-436 cells (B), SUM159 cells (C), and
SUM1315 cells (D). Data represent mean ± SD of
three separate experiments.
(E) Expression levels of FOXC1 protein in different
parental and in-vitro-derived GDC-0449-resistant
BLBC cells.
(F) 5 3 106 control or FOXC1-overexpressing MDA-
MB-468 cells were injected into the fourth mammary
glands of BALB/c nude mice (n = 10 per group).
When tumors reached 100 mm3, mice were treated
with GDC-0449 daily at a dose of 250 mg/kg by oral
gavage. Data represent mean ± SD.
(G) Schematic diagrams for the canonical and
FOXC1-induced SMO-independent Hh signaling
pathways.
See also Figure S7.breast cancer (Hollier et al., 2013), emphasizing the involve-
ment of FOXC members in the regulation of breast CSCs.
One novel aspect of our study is the finding that FOXC1
activates SMO-independent Hh signaling through direct interac-
tion with Gli2, mediating the effect of FOXC1 on CSC properties
in BLBC cells. A more in-depth mechanism of how FOXC1 bind-
ing elicits enhanced Gli2 DNA-binding ability remains to be
determined. Previous studies have reported that Hh signaling
is associated with BLBC (O’Toole et al., 2011) and breast cancer
progression (Kubo et al., 2004). It is also essential for mainte-
nance of CSCs (Coni et al., 2013) and is hyperactive in breast
CSCs with the CD44+/CD24– phenotype (Liu et al., 2006). On
the basis of these studies, we propose a model of the FOXC1-
Gli2 signaling axis as a key regulator for breast CSCs (Figure 7G).
The canonical Hh pathway is activated upon Hh ligand binding
to the cognate receptor Ptch1, which enables SMO to activate
Gli proteins. Hh signaling can also be activated in a non-canon-Cell Reports 13, 1046–1058,ical manner. For example, transforming
growth factor b (TGFb) can activate the
Hh pathway by inducing Gli2 expression
(Dennler et al., 2007). Similarly, mutant
KRAS can induce Gli1 and Gli2 expression
independent of SMO in pancreatic cells
(Ji et al., 2007). Moreover, in esophageal
adenocarcinoma, mTOR/S6K1 pathway
activates Hh signaling through eliciting
SMO-independent Gli1 translocation into
the nucleus (Wang et al., 2012a). Distinct
from the above reports, our study provides
a new non-canonical Hh signaling activa-
tion mechanism mediated by transcription
factor interaction.
Much effort has been directed toward
the development of anti-Hh drugs for
cancer therapy. One of the most widely
used drugs for targeting the Hh pathwayis GDC-0449, the first drug approved by the FDA to treat basal
cell carcinoma (BCC). Several other small-molecule inhibitors
such as LDE225 and IPI-926 (Saridegib) are also being evaluated
in clinical trials (Low and de Sauvage, 2010). It merits mentioning
that all of these drugs target SMO and, to date, appear to be
largely ineffective in solid tumors other than BCC (Kaye et al.,
2012). Our study demonstrates that FOXC1 activates Hh
signaling independently of SMO and thereby induces resistance
to SMO inhibitors in BLBC cells. As such, agents that target the
Hh pathway downstream of SMO by directly blocking Gli func-
tion may be effective to reverse the SMO inhibitor resistance
driven by SMO-independent Gli activation. Indeed, Gli-inhibiting
compounds itraconazole and arsenic trioxide retain Hh-inhibi-
tory activity in anti-SMO-resistant tumors (Kim et al., 2013),
consistent with our finding that GANT61 and ATO inhibit
FOXC1-elicited Hh signaling activation. Moreover, our findings
that FOXC1 is upregulated in SMO inhibitor-resistant BLBCNovember 3, 2015 ª2015 The Authors 1055
cell models and involved in clinical drug resistance further impli-
cate FOXC1 in SMO inhibitor treatment failure.
It is noted that LDE225 is already undergoing clinical trials
for ER– and HER2– breast cancers (https://clinicaltrials.gov/,
NCT01757327). However, current findings allow for reasonable
speculation that LDE225 and other similar drugs may not be
effective against cancers expressing high levels of FOXC1.
Because FOXC1 is also overexpressed in other cancers, it may
serve as a marker for selecting patients who do not benefit
from anti-SMO therapies, and as a target for overcoming anti-
Hh drug resistance.
In summary, we have uncovered a FOXC1-mediated,
SMO-independent Hh signaling mechanism that regulates
CSC properties and anti-Hh/SMO drug resistance. These
data further support a critical role of FOXC1 in BLBC and
warrant continued investigation of FOXC1 as a new avenue
for BLBC treatment.
EXPERIMENTAL PROCEDURES
Cell Culture
Human breast cancer cell lines and HEK293T cells were acquired from Amer-
ican Type Culture Collection (ATCC) and maintained according to ATCC
instructions.
Flow Cytometry
Approximately 2 3 105 cells were suspended in fluorescence-activated cell
sorting (FACS) buffer (1 3 PBS, 1% BSA) and incubated with antibodies at
4C for 30 min. Detection of ALDH activity was performed using the
ALDEFLUOR Assay Kit (STEMCELL Technologies) according to the manufac-
turer’s instruction. Please see the Supplemental Experimental Procedures for
detailed information.
Chromatin Immunoprecipitation
Approximately 5 3 106 cells were collected, and ChIP assays were
performed using the EZ-ChIP Chromatin Immunoprecipitation Kit (EMD Milli-
pore) according to the manufacturer’s instructions. Gli2 antibody (sc-28674,
Santa Cruz Biotechnology) -immunoprecipitated DNA was analyzed by RT-
PCR and real-time PCR. The primers were FAM38B-forward: 50- TACA
TACGTTGGAAGTCTCAG-30 and FAM38B-reverse: 50-CAAGATTCCCAG
CAGGTG-30.
Immunofluorescence and Fluorescence Resonance Energy
Transfer
Cells were placed into chamber slides (Thermo Scientific) at 70%–80%conflu-
ence. Cells were fixed, permeabilized and incubated with primary and second-
ary antibodies. Images were acquired with Leica SP5 X confocal microscope
(Leica Microsystems). Please see the Supplemental Experimental Procedures
for detailed information.
Biotinylated Oligonucleotide Precipitation Assay
The 50-biotinylated oligonucleotides were synthesized from Invitrogen. Com-
plementary oligonucleotides were annealed. Nuclear proteins were extracted
using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scien-
tific). Biotinylated double-stranded oligonucleotides were incubated with
nuclear proteins. DNA-bound proteins were precipitated using Streptavidin
Agarose Beads (Thermo Scientific). Please see the Supplemental Experi-
mental Procedures for detailed information.
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